Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Public ClinicalTrials.gov record NCT03813160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. Approximately 150 subjects will be enrolled in this study at about 60 sites in North America, Europe, and Asia. The planned duration of double-blind treatment with study drug is up to 52 weeks.
Study identification
- NCT ID
- NCT03813160
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 176 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 17, 2018 (Actual)
- Primary completion
- Mar 31, 2021 (Actual)
- Completion
- Oct 5, 2021 (Actual)
- Last update posted
- Aug 16, 2022
2018 – 2021
United States locations
- U.S. sites
- 23
- U.S. states
- 18
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Neurology | Phoenix | Arizona | 85018 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| Attune Health Center | Beverly Hills | California | 90211 | — |
| UCLA Division of Rheumatology | Los Angeles | California | 90095 | — |
| Denver Arthritis Clinic | Denver | Colorado | 80230 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20001 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| University of Miami | Miami | Florida | 33136 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| DelRicht Research | New Orleans | Louisiana | 70115 | — |
| Johns Hopkins Bayview Medical Center | Baltimore | Maryland | 21224 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| University of Minnesota, Division of Rheumatic and Autoimmune Diseases | Minneapolis | Minnesota | 55455 | — |
| Washington University in St. Louis | St Louis | Missouri | 63110 | — |
| Hospital for Special Surgery | New York | New York | 10021 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| University of Pittsburgh, Division of Rheumatology | Pittsburgh | Pennsylvania | 15261 | — |
| MUSC: Department of Neurology | Charleston | South Carolina | 29425 | — |
| Austin Neuromuscular Center | Austin | Texas | 78756 | — |
| Rheumatic Disease Center | Glendale | Wisconsin | 53217 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03813160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2022 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03813160 live on ClinicalTrials.gov.